INOVIO PHARMACEUTICALS Forum: Community User: gerry

Ohaaa………jetzt Tageshoch………läuft💪🙏😌

Ich denke (und hoffe), dass es vor Börsenschluss nochmal hoch geht……

19EUR? Wäre schön :)

Morgen 19€ :)

Same @börsijaner

Ich hab ein gutes Gefühl für die zukunft hier bis ende April

✅ - für mich läuft es mit Daytrading ;) lol.

Verschrei es nicht.. und bis zu meinem EK dauert es noch... morgen kommt der Geschäftsbericht... da bin ich mal gespannt... da gibt es kein bisschen Info im Netz 😷

;)

Es läuft ✅ ;) lol

https://www.sharedeals.de/inovio-pharmaceuticals-beruehmt-beruechtigter-shortseller-attackiert/

https://www.sharedeals.de/inovio-pharmaceuticals-beruehmt-beruechtigter-shortseller-attackiert/

Immerhin...😉

The case for Inovio While Gilead focus on an antiviral treatment for COVID-19, Inovio is working on a vaccine for the novel coronavirus disease. Last week, Inovio announced that it was accelerating the timeline for its experimental COVID-19 vaccine, INO-4800, and expects to begin a phase 1 study in humans in April. Developing coronavirus vaccines isn't new for Inovio. The company is the only drugmaker with a vaccine for preventing a coronavirus in phase 2 testing, although the targeted disease, in this case, is Middle East Respiratory Syndrome (MERS) rather than COVID-19. Still, Inovio's expertise in targeting coronaviruses potentially gives the biotech an advantage. Inovio also has other experimental vaccines in development. Its programs target Ebola, Lassa fever, Zika, and HIV, in addition to COVID-19 and MERS. The company's lead candidate, though, is VGX-3100. Inovio expects to report preliminary results later this year from a late-stage study of the immunotherapy in treating cervical high-grade squamous intraepithelial lesions (HSIL) caused by human papillomavirus (HPV). The biotech is also conducting phase 2 studies of VGX-3100 for treating vulvar HSIL and anal HSIL. AstraZeneca is testing MEDI-0457, a combination of VGX-3100 and IL-12, along with immunotherapy Imfinzi in treating head and neck cancer. The big pharmaceutical company should report results from its phase 2 study featuring the drugs in the second half of 2020. Inovio's pipeline also includes three other drugs in clinical testing. The company plans to announce overall survival data after 12 and 18 months later this year from a phase 2 study evaluating INO-5401 in treating aggressive brain cancer glioblastoma multiforme (GBM). It's evaluating INO-5051 in a phase 2 study for treating prostate cancer. Inovio also plans to initiate a phase 1/2 study in 2020 for INO-3107 in treating recurrent respiratory papillomatosis (RRP). Better coronavirus stock It's not all sunshine and roses for Gilead and Inovio. RBC Capital Markets think that remdesivir has only a 50% chance of success in being effective at treating COVID-19. Gilead's hepatitis C franchise sales continue to fall. As for Inovio, short-seller Citron Research recently slammed the company's coronavirus program and thinks its shares will plunge to a fraction of the current price. So which of these biotech stocks is the better pick right now? I think that Gilead Sciences is the clear winner. The company is profitable, while Inovio isn't. It has a much larger and more diversified pipeline. And even if its prospects of achieving success in treating COVID-19 come down to essentially a flip of the coin, I think Gilead's chances are higher than Inovio's are with its experimental COVID-19 vaccine. Gilead Sciences is the better coronavirus stock.

@Anas: sorry geht nicht anders. Schaut bei motleyfool ...

Stocky 9 milli nur von trump aus China waren es 6.5 milli